Oculis (NASDAQ:OCS) Rating Increased to Strong-Buy at Guggenheim

Guggenheim upgraded shares of Oculis (NASDAQ:OCS) to a strong-buy rating in a report published on Wednesday morning,Zacks.com reports.

A number of other research analysts have also recently commented on the stock. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research note on Tuesday, April 21st. HC Wainwright increased their price objective on Oculis from $44.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. JPMorgan Chase & Co. increased their price objective on Oculis from $38.00 to $42.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Stifel Nicolaus increased their price objective on Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $49.38.

Oculis Stock Up 11.1%

Shares of NASDAQ OCS opened at $31.00 on Wednesday. Oculis has a one year low of $16.00 and a one year high of $34.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18. The firm’s 50 day simple moving average is $27.44 and its two-hundred day simple moving average is $24.83. The stock has a market capitalization of $1.80 billion, a P/E ratio of -14.55 and a beta of 0.38.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. The business had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.25 million. As a group, analysts expect that Oculis will post -2.21 EPS for the current fiscal year.

Institutional Trading of Oculis

A number of institutional investors have recently made changes to their positions in the stock. Gildi lifeyrissjodur purchased a new stake in Oculis in the fourth quarter worth $50,250,000. Aberdeen Group plc lifted its stake in Oculis by 39.4% in the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after acquiring an additional 493,827 shares during the period. SR One Capital Management LP lifted its stake in Oculis by 98.8% in the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after acquiring an additional 318,522 shares during the period. Perceptive Advisors LLC purchased a new stake in Oculis in the fourth quarter worth $9,862,000. Finally, Alyeska Investment Group L.P. lifted its stake in Oculis by 152.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after acquiring an additional 200,000 shares during the period. Hedge funds and other institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.